After hours: March 17 at 6:01:05 PM EDT ...

Nektar Therapeutics (NKTR) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of a loss of $0.13 per share. This compares to loss of $0.22 per share a year ago.

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Nektar Therapeutics (NKTR – Research Report), with a price target of $7.00. The company’s shares closed ...

18:10 EDT Nektar (NKTR) up 12% to 91c after Oppenheimer upgrade with $6 target Easily identify stocks' risks and opportunities. Discover stocks' market position with detailed competitor analyses.

SAN FRANCISCO (AP) — SAN FRANCISCO (AP) — Nektar Therapeutics (NKTR) on Wednesday reported fourth-quarter earnings of $7.3 million. The San Francisco-based company said it had net income of 3 ...

Just days after revealing that it was in discussions with Nektar Therapeutics over a possible merger, PureTech Health has said the negotiations have been terminated by mutual agreement. In a ...

SAN FRANCISCO - Nektar Therapeutics (NASDAQ:NKTR), currently trading at $0.87 with a market capitalization of $162.5 million, announced today that it has achieved target enrollment for its Phase ...

Good day, and thank you for standing by. Welcome to the Nektar Therapeutics Fourth Quarter 2024 financial results conference call. At this time, all participants are in a listen-only mode.

(RTTNews) - Below are the earnings highlights for Nektar Therapeutics (NKTR): Earnings: $7.26 million in Q4 vs. -$42.08 million in the same period last year. EPS: $0.03 in Q4 vs. -$0.22 in the ...